Education 【 display / non-display 】

Education 【 display / non-display 】

• 　

  -

  1988

  Sapporo Medical University   School of Medicine   Department of Medicine  

Degree 【 display / non-display 】

Degree 【 display / non-display 】

• Sapporo Medical University   MD, PhD (Medical Science)

Research Experience 【 display / non-display 】

Research Experience 【 display / non-display 】

• 2018.01

  -

  Now

  Sapporo Medical University   Center for Medical Education   Professor

• 2018.01

  -

  Now

  Sapporo Medical University   Graduate School of Medicine   Professor

• 2008.06

  -

  2017.12

  Sapporo Medical University   School of Medicine   Associate Professor

• 2004.04

  -

  2008.05

  Sapporo Medical University   School of Medicine   Assistant Professor

• 1999.10

  -

  2004.03

  Sapporo Medical University   School of Medicine   Instructor

Professional Memberships 【 display / non-display 】

Professional Memberships 【 display / non-display 】

• 2021.04

  -

  Now

  Japan Association for Medical Informatics

• 2018.04

  -

  Now

  Japan Society for Medical Education

• 2010.01

  -

  Now

  International Society of Oncology & BioMarkers (ISOBM)

• 2009.01

  -

  Now

  THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

• 2005.01

  -

  Now

  Japanese Society of Molecular Medicine

display all >>

Research Areas 【 display / non-display 】

Research Areas 【 display / non-display 】

• Life sciences   Genomics  

• Life sciences   Tumor biology  

• Life sciences   Gastroenterology  

Affiliation 【 display / non-display 】

Affiliation 【 display / non-display 】

• Sapporo Medical University   Biology Division, Department of Liberal Arts and Sciences, Center for Medical Education   Professor  

Research Interests 【 display / non-display 】

Research Interests 【 display / non-display 】

• Cancer-related genes

• Cancer genetics

• p53 family

• Digestive cancer

• p53

display all >>

Papers 【 display / non-display 】

Papers 【 display / non-display 】

• Impact of Sensitive Circulating Tumor DNA Monitoring on CT Scan Intervals During Postoperative Colorectal Cancer Surveillance

  Tomoko Sasaki, Takeshi Iwaya, Mizunori Yaegashi, Masashi Idogawa, Hayato Hiraki, Masakazu Abe, Yuka Koizumi, Noriyuki Sasaki, Akiko Yashima-Abo, Ryosuke Fujisawa, Fumitaka Endo, Shoichiro Tange, Koki Otsuka, Akira Sasaki, Mari Masuda, Masashi Fujita, Hidewaki Nakagawa, Fumiaki Takahashi, Yasushi Sasaki, Takashi Tokino, Satoshi S. Nishizuka

  Annals of Surgery Open ( Ovid Technologies (Wolters Kluwer Health) )  6 ( 1 ) e549 - e549  2025.02  [Refereed]

  　View Summary

  Objective: This study investigated whether digital polymerase chain reaction (dPCR)-based circulating tumor DNA (ctDNA) monitoring can allow longer intervals between computed tomography (CT) scans during postoperative surveillance of colorectal cancer (CRC). Background: Practical guidelines still recommend intensive postoperative surveillance of CRC using periodical CT scans and serum carcinoembryonic antigen testing. Methods: The longitudinal dynamics of ctDNA for 52 patients with CRC as measured by dPCR using probes targeting 87 individual tumor-specific mutations (1–5 per patient) were compared with results from conventional (ie, clinical) surveillance using serum tumor markers and CT. Results: A total of 382 CT procedures were carried out for the patient cohort (3.3/year per patient) and the median lead time from ctDNA relapse to clinical relapse was 182 days (range, 0–376 days). If the CT interval was annual, potential delays in the detection of clinical relapse would have occurred for 7 of the 10 patients who experienced clinical relapse (9 of 13 events), with a median delay of 164 days (range, 0–267 days). If annual CT surveillance was performed together with ctDNA monitoring, 218 (57.1%) CTs would not have been needed to detect the first clinical relapse. In addition, the ctDNA monitoring would have provided a lead time of 339 days for detection of clinical relapse (range, 42–533 days). Conclusions: Our findings suggest that the ctDNA monitoring as part of postoperative surveillance and clinical relapse detection for patients with CRC could allow the CT interval to be lengthened. Trial Registration: This trial was registered with University Hospital Medical Information Network Clinical Trial Registry (UMIN000045114).

  DOI

• Targeted dynamic phospho-proteogenomic analysis of gastric cancer cells suggests host immunity provides survival benefit.

  Kohei Kume, Midori Iida, Takeshi Iwaya, Akiko Yashima-Abo, Yuka Koizumi, Akari Endo, Kaitlin Wade, Hayato Hiraki, Valerie Calvert, Julia Wulfkuhle, Virginia Espina, Doris R Siwak, Yiling Lu, Kazuhiro Takemoto, Yutaka Suzuki, Yasushi Sasaki, Takashi Tokino, Emanuel Petricoin 3rd, Lance A Liotta, Gordon B Mills, Satoshi S Nishizuka

  Molecular & cellular proteomics : MCP     100870 - 100870  2024.10  [Refereed]  [International journal]

  　View Summary

  Despite of massive emergence of molecular targeting drugs, the mainstay of advanced gastric cancer (GC) therapy is DNA-damaging drugs. Using a reverse-phase protein array-based proteogenomic analysis of a panel of eight GC cell lines, we identified genetic alterations and signaling pathways, potentially associated with resistance to DNA-damaging drugs, including 5-fluorouracil (5FU), cisplatin, and etoposide. Resistance to cisplatin and etoposide, but not 5FU, was negatively associated with global copy number loss, vimentin expression, and caspase activity, which are considered hallmarks of previously established EMT subtype. The segregation of 19,392 protein expression time courses by sensitive and resistant cell lines for the drugs tested revealed that 5FU-resistant cell lines had lower changes in global protein dynamics, suggesting their robust protein level regulation, compared to their sensitive counterparts, whereas the cell lines that are resistant to other drugs showed increased protein dynamics in response to each drug. Despite faint global protein dynamics, 5FU-resistant cell lines showed increased STAT1 phosphorylation and PD-L1 expression in response to 5FU. In publicly available cohort data, expression of STAT1 and NFκB target genes induced by proinflammatory cytokines was associated with prolonged survival in GC. In our validation cohort, total lymphocyte count (TLC), rather than PD-L1 positivity, predicted a better relapse-free survival rate in GC patients with 5FU-based adjuvant chemotherapy than those with surgery alone. Moreover, TLC+ patients who had no survival benefit from adjuvant chemotherapy were discriminated by expression of IκBα, a potent negative regulator of NFκB. Collectively, our results suggest that 5FU resistance observed in cell lines may be overcome by host immunity or by combination therapy with immune checkpoint blockade.

  DOI PubMed

• Synchronous cancers of the stomach and esophagus in a patient with autoimmune gastritis and pernicious anemia: a case report and review of the literature.

  Toshiyuki Kubo, Yasushi Adachi, Yasushi Sasaki, Yasuyo Adachi, Yukinari Yoshida, Takao Endo, Yoshifumi Ishii, Hiroaki Takahashi, Akira Goto

  International cancer conference journal   13 ( 4 ) 367 - 373  2024.10  [Refereed]  [International journal]

  　View Summary

  Type-A gastritis/autoimmune gastritis (AIG) has gained renewed attention due to declining Helicobacter pylori infection rates and increasing eradication. AIG is associated with pernicious anemia (PA) and is prone to complicate various tumors, such as gastric cancer and neuroendocrine tumors. This report describes a case of AIG with PA in which gastric and esophageal cancers arose simultaneously. An 86-year-old woman had been diagnosed with PA and AIG 9 years earlier. As routine blood tests revealed high levels of carcinoembryonic antigen, she underwent esophagogastroduodenoscopy, which revealed a type 0-IIa lesion in the middle part of the stomach and a type 0-IIa + IIb lesion in the lower esophagus. Endoscopic submucosal dissection was performed on both lesions, since neither distant nor lymph node metastases were identified. Histological examination showed gastric tubular adenocarcinoma and esophageal squamous cell carcinoma. Immunohistology revealed that cells from neither cancer expressed gastrin, gastrin receptor, or p53. Whole-exome sequencing showed 8 gene mutations in the esophageal cancer and 6 mutations in 5 genes in the gastric cancer. The reason for the lack of p53 immunostaining was that TP53 was mutated in these cancers, although TP53 mutations differed. Thus, TP53 mutations may not be detected by immunostaining alone. When treating patients with AIG/PA, clinicians must be aware of the possibility of esophageal cancer coexisting with gastric cancer.

  DOI PubMed

• 口腔がんにおける悪性化関連遺伝子群転写抑制機構の解明(Nuclear protein X represses the transcription of malignancy-related genes in oral cancer cell lines)

  丹下 正一朗, 後藤 生子, 川島 秀器, 井戸川 雅史, 佐々木 泰史, 時野 隆至

  日本癌学会総会記事 ( (一社)日本癌学会 )  83回   P - 2241  2024.09

• Association of serum superoxide dismutase activity and the incidence of colorectal cancer in a nested case-control study.

  Yasushi Adachi, Masanori Nojima, Mitsuru Mori, Hiro-O Yamano, Yasushi Sasaki, Hiroshi Nakase, Yingsong Lin, Kenji Wakai, Akiko Tamakoshi

  Cancer epidemiology   87   102455 - 102455  2023.09  [Refereed]  [International journal]

  　View Summary

  BACKGROUND: Superoxide dismutase (SOD) is an antioxidant enzyme that degrades superoxide, a major causative factor in carcinogenesis. We assessed associations between serum SOD activities and incidence of colorectal carcinoma (CRC) in a case-control study nested in the Japan Collaborative Cohort (JACC) study. METHODS: At baseline, 39,242 subjects donated serum samples. Participants diagnosed with CRC during follow-up were regarded as cases. Odds ratios (ORs) for CRC incidence associated with SOD were evaluated with conditional logistic regression models. In the current study, 176 cases and 524 controls were analyzed. RESULTS: For the overall cohort, a decreasing trend in risk of CRC with increasing SOD was observed (P for trend=0.054) and the fourth quartile of SOD level showed the lowest risk compared to the first (OR=0.52, 95% confidence interval [CI]=0.29-0.93). This was significant in men (P for trend=0.001), with the fourth quartile of SOD level showing the lowest risk compared to the first (OR, 0.23; 95%CI, 0.09-0.60). It was also exclusively observed for rectal cancer and left-sided CRC (P for trend, 0.037 and 0.020, respectively), with the fourth quartile again showing the lowest risk compared to the first (OR, 0.28 and 0.38; 95%CI, 0.09-0.84 and 0.16-0.91, respectively). Limiting subjects to those followed-up over 2 years, all trends remained unchanged. CONCLUSIONS: Our findings suggest that serum SOD activity correlates inversely with risk of CRC, particularly in men and individuals with rectal cancer/left-sided CRC.

  DOI PubMed J-GLOBAL

display all >>

Books and Other Publications 【 display / non-display 】

Books and Other Publications 【 display / non-display 】

• 分子標的療法の基礎と臨床

  佐々木 泰史, 時野 隆至( Part： Contributor, p53, p63, p73の機能とp53ファミリーを標的としたがん療法への応用)

  篠原出版新社  2005

• 内科疾患クリニカルガイド 消化器・免疫・血液・代謝疾患

  佐々木 泰史( Part： Contributor, 癌性疼痛治療の実際)

  中山書店  1999

• 日本臨床別冊巻 肝・胆道系症候群 肝臓編（上巻）

  佐々木泰史, 坂本裕史, 日野田裕治, 矢花剛( Part： Joint author, 肝粘表皮癌、肝内胆管粘表皮癌)

  日本臨床社  1995.04

• 血液学

  今井浩三, 佐々木泰史, 辻崎正幸( Part： Contributor, 原発性マクログロブリン血症)

  中外医学社  1991

• Therapeutic plasmapheresis VIII

  Suga M, Tsuchida M, Arimura Y, Matsuno K, Sasaki Y, Miyachi T, Ishida S, Yachi A( Part： Contributor, Basic and clinical evaluation of anion exchange resin column for treatment of jaundice)

  ISAO Press  1989

Misc 【 display / non-display 】

Misc 【 display / non-display 】

• 内視鏡的切除により診断できた皮膚様食道扁平上皮癌

  足立 靖, 菊地 剛史, 後藤 啓, 吉田 幸成, 石井 良文, 高橋 宏明, 佐々木 泰史, 仲瀬 裕志, 遠藤 高夫

  日本消化管学会雑誌 ( (一社)日本消化管学会 )  8 ( Suppl. ) 360 - 360  2024.01

• 症例報告からPrecision Medicineへ-第1部- 悪性貧血を伴う自己免疫性胃炎における胃癌と食道癌の同時発生(Simultaneous cancers of the stomach and esophagus in autoimmune gastritis with pernicious anemia)

  足立 靖, 久保 俊之, 佐々木 泰史, 安達 靖代, 吉田 幸成, 遠藤 高夫, 石井 良文, 高橋 宏明, 後藤 啓

  日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  61回   ICCJ1 - 3  2023.10

• Association of serum superoxide dismutase activity and the incidence of colorectal cancer in a nested case-control study.

  Yasushi Adachi, Masanori Nojima, Mitsuru Mori, Hiro-O Yamano, Yasushi Sasaki, Hiroshi Nakase, Yingsong Lin, Kenji Wakai, Akiko Tamakoshi

  Cancer epidemiology ( (一社)日本癌学会 )  87   102455 - 102455  2023.09  [International journal]

  　View Summary

  BACKGROUND: Superoxide dismutase (SOD) is an antioxidant enzyme that degrades superoxide, a major causative factor in carcinogenesis. We assessed associations between serum SOD activities and incidence of colorectal carcinoma (CRC) in a case-control study nested in the Japan Collaborative Cohort (JACC) study. METHODS: At baseline, 39,242 subjects donated serum samples. Participants diagnosed with CRC during follow-up were regarded as cases. Odds ratios (ORs) for CRC incidence associated with SOD were evaluated with conditional logistic regression models. In the current study, 176 cases and 524 controls were analyzed. RESULTS: For the overall cohort, a decreasing trend in risk of CRC with increasing SOD was observed (P for trend=0.054) and the fourth quartile of SOD level showed the lowest risk compared to the first (OR=0.52, 95% confidence interval [CI]=0.29-0.93). This was significant in men (P for trend=0.001), with the fourth quartile of SOD level showing the lowest risk compared to the first (OR, 0.23; 95%CI, 0.09-0.60). It was also exclusively observed for rectal cancer and left-sided CRC (P for trend, 0.037 and 0.020, respectively), with the fourth quartile again showing the lowest risk compared to the first (OR, 0.28 and 0.38; 95%CI, 0.09-0.84 and 0.16-0.91, respectively). Limiting subjects to those followed-up over 2 years, all trends remained unchanged. CONCLUSIONS: Our findings suggest that serum SOD activity correlates inversely with risk of CRC, particularly in men and individuals with rectal cancer/left-sided CRC.

  DOI PubMed

• 血清可溶性Fas値と肝臓癌罹患リスク(Serum soluble Fas levels and incidence of liver cancer)

  足立 靖, 野島 正寛, 森 満, 久保 俊之, 阿久津 典之, 佐々木 泰史, 仲瀬 裕志, 遠藤 高夫, 林 櫻松, 若井 建志, 玉腰 暁子

  日本癌学会総会記事 ( (一社)日本癌学会 )  82回   125 - 125  2023.09

• Prospective observational study of monitoring gene alterations in plasma cell-free DNA using droplet digital PCR system during anti-EGFR antibody treatment in patients with RAS wild-type advanced colorectal cancer.

  Naoki Takahashi, Keishi Nakamura, Yosuke Kito, Eiji Kubota, Masako Asayama, Yosuke Kumekawa, Hiroki Hara, Tomohiro Matsushima, Kunihiro Tsuji, Hiromi Kataoka, Akihiro Tsuyada, Yasushi Sasaki, Masashi Idogawa, Takashi Tokino, Takeshi Sawada

  Journal of Clinical Oncology ( American Society of Clinical Oncology (ASCO) )  41 ( 4_suppl ) 172 - 172  2023.02

  Research paper, summary (international conference)  

  　View Summary

  172 Background: Anti-EGFR antibody is recommended as one of the standard treatments in patients with RAS wild-type advanced colorectal cancer (CRC). Few reports have evaluated low-frequency subclones of alterations in EGFR signaling pathway genes in plasma cell-free DNA (cfDNA) during anti-EGFR treatment in prospective cohort of advanced CRC patients. Methods: Key inclusion criteria of this study was as follows: 20 years old and over, performance status 0 to 2, metastatic or recurrent CRC (adenocarcinoma), RAS wild-type CRC diagnosed by PCR-rSSO using tumor tissue, no prior use of anti-EGFR antibody. Plasma samples were prospectively collected at pre-treatment, at 4, 10 weeks, every 10 weeks thereafter, and at the end of the anti-EGFR treatment. With QX200 Droplet Digital PCR platform, we analyzed hotspot mutations of KRAS, NRAS, BRAF, and PIK3CA and copy number (CN) variant of HER2 and MET using plasma samples of pre- and post-treatment as well as during treatment (limited to patients with any gene alterations at pre- and post-treatment). Results: Total 50 patients were registered in this study, but 3 patients were excluded because inclusion criteria were not met. Finally, 47 patients were included in full analysis set. In 15 patients (31.9%), genetic alterations including KRAS (G12G13: 10.1%, A59Q61: 2.2%), NRAS (G12G13: 2.2%, Q61: 2.1%), BRAF (V600: 6.4%) , PIK3CA (E545: 4.3%, H1047: 4.3%) , and HER2 (amplification: 6.5%) were detected in pre-treatment samples. Analysis of pre-treatment samples showed that response rates of patients with any gene alterations (N = 13) and that without any gene alterations (N = 29) were 30.8% and 58.6%, respectively (p = 0.095). When the cut-off of variant allele frequency (VAF) was set as 0.5% in patients with any gene mutations, the response rates for cases with VAF ≥0.5% (N = 6) and those with VAF < 0.5% (N = 7) were 0% and 57.1%, respectively (p = 0.049). Among 41 patients with detectable target lesions by CT scan, there was significant difference in percentage of best tumor shrinkage between patients with gene alterations and those without gene alterations (32.1% vs 10.5%, p = 0.037), when cut-off VAF of any gene mutations was set as 0.5% and cut-off CN of HER2 or MET was set as 4 at pre-treatment. Due to dynamics of each gene alteration in cfDNA during treatment, mutations of KRAS A59Q61, NRAS Q61, and MET amplification were characterized as acquired alterations which were newly detected after the administration of anti-EGFR antibodies. Conclusions: Our study demonstrated the clinical relevance of minor mutant subclones in EGFR signaling pathway genes in plasma for predicting response to anti-EGFR treatment. Although sample size of this study was small, preferable threshold for distinguishing responders from non-responders may be 0.5% as VAF of these gene mutations. Clinical trial information: 000034923 .

  DOI

display all >>

Industrial Property Rights 【 display / non-display 】

Industrial Property Rights 【 display / non-display 】

• がんを処置するための医薬

  井戸川 雅史, 大箸 智子, 佐々木 泰史, 時野 隆至

  Patent

  J-GLOBAL

• p53ファミリーキメラ分子およびその使用

  時野 隆至, 井戸川 雅史, 佐々木 泰史

  Patent

  J-GLOBAL

• アポトーシス誘導剤

  特許第5630769号

  井戸川雅史, 佐々木泰史, 時野隆至

  Patent

  J-GLOBAL

• アポトーシス誘導剤

  井戸川雅史, 佐々木泰史, 時野隆至

  Patent

  J-GLOBAL

Other 【 display / non-display 】

Other 【 display / non-display 】

• 緩和ケア研修会修了（北-4252号）

  2017.05

  　

  　

• General Clinical Oncologist (Japanese Board of Cancer Therapy)（No. 09100061）

  2010.04

  -

  Now

• 日本癌治療学会臨床試験登録医 （0985号）

  2004.08

  -

  Now

• Board Certified Hepatologist of the Japan Society of Hepatology（No. 3150）

  1999.04

  -

  Now

• Board Certified Fellow of the Japan Gastroenterological Endoscopy Society（No. 0094005）

  1994.12

  -

  Now

display all >>

Awards 【 display / non-display 】

Awards 【 display / non-display 】

• 北海道医師会賞

  2021.10  

  Winner： Yasushi Sasaki

• 北海道知事賞

  2021.10   がん抑制遺伝子p53とそのファミリー (p73、p63)の機能解明

  Winner： Yasushi Sasaki

• 第14回日本消化器関連学会週間優秀演題賞

  2006.12   日本消化器関連学会週間  

  Winner： Yasushi Sasaki

• 第44回日本癌治療学会総会優秀演題賞

  2006.10   日本癌治療学会総会  

  Winner： Yasushi Sasaki

• 札幌医科大学医師会学術賞

  2003.03   札幌医科大学医師会  

  Winner： Yasushi Sasaki

Research Projects 【 display / non-display 】

Research Projects 【 display / non-display 】

• p53ネットワーク破綻による翻訳動態の変化と発がん過程における意義

  2024( 56th ) Research Grants of Princess Takamatsu Cancer Research Fund

  Project Year :

  2025.03

  　

  　

   

  Yasushi Sasaki

  Authorship： Principal investigator

• Development of molecular targeted therapy for primary central nervous system lymphomas based on genome and metabolome data.

  Grant-in-Aid for Scientific Research (B)

  Project Year :

  2024.04

  -

  2026.03

   

  山中 龍也, 高島 康郎, 川口 淳, 佐々木 泰史, 深井 順也

• p53の機能獲得変異に関わる小型タンパク質の探索と機能解明

  日本イーライリリー イノベーション研究助成

  Project Year :

  2023.12

  -

  2025.03

   

  佐々木泰史

  Authorship： Principal investigator

• p53ネットワークに関わるマイクロプロテインの探索と食道扁平上皮癌新規治療戦略

  科学研究費助成事業 基盤研究(C)

  Project Year :

  2023.04

  -

  2026.03

   

  佐々木 泰史

  Authorship： Principal investigator

• 非乳頭部十二指腸腺癌の2つの独立した発癌経路の検証とその分子機構の解明

  金沢大学がん進展制御研究所共同研究（一般研究、新規）

  Project Year :

  2023.04

  -

  2024.03

   

  佐々木泰史, 澤田 武, 中村 慶史, 源 利成

  Authorship： Principal investigator

display all >>

Committee Memberships 【 display / non-display 】

Committee Memberships 【 display / non-display 】

• 2022.04

  -

  Now

    Councilor, The Japanese Electrophoresis Society

• 2012.01

  -

  Now

    Councilor, The Japan Society of Drug Delivery System

• 2011.01

  -

  Now

    Councilor, Japanese Society of Molecular Medicine

• 2010.01

  -

  Now

    Councilor, The Japanese Cancer Association

• 2005.01

  -

  Now

    Councilor, Japanese Society of Gastroenterology

display all >>

Social Activities 【 display / non-display 】

Social Activities 【 display / non-display 】

• Advisor, Sapporo Medical University Golf Club

  2014.04

  -

  Now

Academic Activities 【 display / non-display 】

Academic Activities 【 display / non-display 】

• Translational Oncology: International Advisory Review Board

  Peer review

  2021

  -

  Now

• Cancer Treatment and Research Communications: Editorial Board

  Peer review

  2021

  -

  Now

• Gastroenterology Insights: Editorial Board

  Peer review

  2019

  -

  Now

• Molecular Medicine Reports: Editorial Board

  Peer review

  2018

  -

  Now